TScan Therapeutics (TCRX) Earnings Date & Reports

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

TCRX is expected to report earnings to fall 6.67% to -28 cents per share on May 13

TScan Therapeutics TCRX Stock Earnings Reports

Q1'25

Est.

$-0.28

Q4'24

Missed

by $0.01

Q3'24

Beat

by $0.06

Q2'24

Est.

$-0.28

Q1'24

Missed

by $0.06

The last earnings report on March 05 showed earnings per share of -30 cents, missing the estimate of -28 cents. With 1.01M shares outstanding, the current market capitalization sits at 81.49M.

View a ticker or compare two or three

Compare

TCRX